The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
Mounjaro · Zepbound · LY3298176
Among the most thoroughly trialed compounds on this site — 25,000+ patients across the SURPASS and SURMOUNT programs.
Tirzepatide is currently the most effective FDA-approved weight loss medication and one of the few compounds on this site with A-grade evidence. For appropriate patients — meaningful obesity or type 2 diabetes — the risk/benefit is strongly favorable.
Weight: 15.0% mean loss at 5mg, 19.5% at 10mg, 20.9% at 15mg over 72 weeks in SURMOUNT-1 (non-diabetic obesity) [3]. Glycemia: A1c reduction of 1.9–2.6% in type 2 diabetes trials, with high rates of A1c <5.7% [6, 7]. Cardiovascular: SURPASS-CVOT pending readout will define the cardiovascular benefit [8]. Renal: improvements in albuminuria seen in trial subgroups [9]. Liver: significant MASH resolution and fibrosis improvement — 62% MASH resolution at 52 weeks in SYNERGY-NASH at top dose [10].
Tirzepatide was developed by Eli Lilly as the first dual GLP-1/GIP receptor agonist intended to outperform the GLP-1-only class [1]. FDA approval for type 2 diabetes came in May 2022 under the brand name Mounjaro [2]. The obesity indication was approved in November 2023 under the brand name Zepbound, following the SURMOUNT trial program [3]. Demand has dramatically exceeded supply since launch.
Tirzepatide is the current frontier of the GLP-1 class — head-to-head against semaglutide it consistently produces greater weight loss. The next generation (retatrutide, survodutide) adds glucagon receptor agonism on top.
Tirzepatide is a 39-amino-acid synthetic peptide engineered around the GIP backbone with modifications that give it cross-reactivity at both the GLP-1 and GIP receptors [1]. A C20 fatty acid is attached via a linker to enable albumin binding, which is the basis for the ~5-day half-life that supports once-weekly dosing [4].
GLP-1 receptor agonism produces glucose-dependent insulin secretion, delayed gastric emptying, and central appetite suppression via hindbrain and hypothalamic circuits [1]. GIP receptor agonism adds an additional axis: improved adipocyte function and possibly enhanced satiety beyond what GLP-1 alone delivers [5]. The combination produces synergistic effects on weight and glycemia that exceed either pathway alone.
GIP receptor pharmacology was historically ambiguous — some data suggested GIP agonism could worsen obesity. Tirzepatide's clinical success indicates the dual approach overrides those concerns, and has reshaped how the field thinks about incretin combinations.
Detailed transcriptomic effects of tirzepatide are still being characterized. Animal work shows altered hypothalamic POMC/AgRP signaling consistent with appetite suppression, and adipocyte gene expression changes consistent with improved insulin sensitivity [5].
The SURPASS program (1-5, SURPASS-J, SURPASS-AP) established tirzepatide in type 2 diabetes against placebo, semaglutide, insulin glargine, and insulin degludec [6, 7, 11, 12]. The SURMOUNT program (1-4) established the obesity indication, including SURMOUNT-1 in non-diabetic obesity [3], SURMOUNT-2 in obesity with diabetes [13], SURMOUNT-3 with intensive lifestyle co-intervention [14], and SURMOUNT-4 examining maintenance after lead-in [15]. Total enrollment exceeds 25,000.
Tirzepatide is one of very few compounds on this site with a true A-grade evidence rating — multiple large, well-conducted RCTs with consistent results. Most peptides on this site are C-grade or below.
Standard titration: 2.5 mg weekly for 4 weeks (tolerability lead-in, not therapeutic), then increase by 2.5 mg every 4 weeks as tolerated up to a maximum of 15 mg weekly [2]. Many patients stop at 5 or 10 mg if weight loss is satisfactory and side effects are manageable.
| Goal | Dose | Frequency | Cycle |
|---|---|---|---|
| Lead-in (Week 1–4) | 2.5 mg | Weekly SC | Tolerability only, not therapeutic |
| Therapeutic start (Week 5–8) | 5 mg | Weekly SC | First clinically active dose |
| Common maintenance (Week 13–16) | 10 mg | Weekly SC | Many patients stop here |
| Maximum (Week 21+) | 15 mg | Weekly SC | If tolerability allows |
| Phase | Weeks | Dose | Monitoring focus |
|---|---|---|---|
| Lead-in | 1–4 | 2.5 mg | Tolerability only, not therapeutic. Assess GI side effects. |
| Therapeutic start | 5–8 | 5 mg | First clinically active dose. Weight loss begins. |
| Titration | 9–20 | 7.5–12.5 mg | Increase 2.5 mg every 4 weeks as tolerated. |
| Maximum | 21+ | 15 mg | If tolerability allows. Monitor lean mass and adequate protein intake. |
GI effects: nausea (most common), vomiting, diarrhea, constipation [3, 6]. Generally most pronounced during titration. Pancreatitis: rare but documented. Gallbladder: increased gallstone risk with rapid weight loss generally. Thyroid: FDA boxed warning for medullary thyroid carcinoma based on rodent data; not seen in human studies but contraindicated in patients with personal or family history of MTC or MEN-2 [2].
Personal or family history of medullary thyroid carcinoma (MTC), or multiple endocrine neoplasia syndrome type 2 (MEN-2).
Slow titration and small frequent meals are the most effective GI mitigation. Hydration matters — dehydration secondary to GI effects has driven most of the reported acute kidney injury cases.
Cagrilintide (amylin analog) + GLP-1 combinations are in late-stage development. In current practice, metformin is commonly retained alongside tirzepatide in diabetes patients. Resistance training and adequate protein intake (1.6 g/kg lean mass) are the standard recommendations to mitigate lean-mass loss during rapid weight loss.
Cost: list price ~$1,000/month; insurance coverage varies dramatically. Supply: largely resolved since late 2024, ending the compounded GLP-1 era; gray-market and "research chemical" tirzepatide remains widely available with the usual quality caveats. Injection: pen-delivered subcutaneous, abdomen or thigh, weekly. Onset: appetite suppression often noticeable within 1–2 weeks.
See structured list below.
Comprehensive reference list below. The SURPASS and SURMOUNT publications in NEJM and Lancet are the primary sources for efficacy and safety data.
Tirzepatide is currently the most effective FDA-approved weight loss medication and one of the few compounds on this site with A-grade evidence. The next generation (retatrutide, survodutide) may eclipse it within 2–3 years.
A-grade evidence. FDA-approved for diabetes and obesity. 15–22% mean weight loss. GI side effects common but manageable. Thyroid contraindication for MTC/MEN-2.
Tirzepatide is currently the most effective FDA-approved weight loss medication and one of the few compounds on this site with A-grade evidence. For appropriate patients — meaningful obesity or type 2 diabetes — the risk/benefit is strongly favorable.
Tirzepatide is the current standard-of-care anchor for the modern GLP-1 era. Head-to-head against semaglutide it consistently produces greater weight loss. The next generation adds glucagon receptor agonism.
Tirzepatide is the most effective FDA-approved weight loss medication available in 2026, with A-grade evidence from the SURPASS and SURMOUNT programs. GI side effects are the main practical limit; the MTC/MEN-2 contraindication is the firm hard stop. The standard-of-care anchor for the modern GLP-1 era.